Plasma Levels of IL-6 in Patients with Untreated Major Depressive Disorder: Comparison with Catecholamine Metabolites

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2019 Nov 6

PMID 31686824

Citations 3

Authors

Reiji Yoshimura

Taro Kishi

Nakao Iwata

Affiliations

Soon will be listed here.

Abstract

Objective: IL-6 and catecholamines play roles in the pathophysiology of major depressive disorder (MDD).

Aim: The present study investigated associations between plasma IL-6 and plasma catecholamine metabolites in patients with MDD.

Participants And Methods: A total of 148 patients (male/female 65/83, age 49.5±12.1 years) who met the criteria for MDD based on the and 40 participants as healthy controls (HC; male/female 23/17, age 44.0±10.5 years) were enrolled in the present study. Plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and homovanillic acid (HVA) were analyzed using high-performance liquid chromatography, and plasma IL-6 levels were measured using ELISA.

Results: No correlations were observed among plasma IL-6 levels, MHPG levels, and HVA levels in patients with MDD. Plasma IL-6 levels in patients with MDD were significantly higher than in the HC. A positive correlation was found between plasma IL-6 levels and Hamilton Rating Scale for Depression-17 scores.

Conclusion: No correlations existed between plasma IL-6 levels and plasma catecholamine metabolite levels in patients with MDD, and the severity of depressive state was related to plasma IL-6 levels in MDD.

Citing Articles

Alzheimer's Disease: Models and Molecular Mechanisms Informing Disease and Treatments.

Nystuen K, McNamee S, Akula M, Holton K, Deangelis M, Haider N Bioengineering (Basel). 2024; 11(1).

PMID: 38247923 PMC: 10813760. DOI: 10.3390/bioengineering11010045.

Associations of Serum Cytokines, Growth Factors, and High-Sensitivity C-Reactive Protein Levels in Patients with Major Depression with and without Type 2 Diabetes Mellitus: An Explanatory Investigation.

Hoshikawa T, Okamoto N, Natsuyama T, Fujii R, Ikenouchi A, Honma Y Neuropsychiatr Dis Treat. 2022; 18:173-186.

PMID: 35140467 PMC: 8820450. DOI: 10.2147/NDT.S350121.

Rheumatoid Arthritis: The Impact of Mental Health on Disease: A Narrative Review.

Lwin M, Serhal L, Holroyd C, Edwards C Rheumatol Ther. 2020; 7(3):457-471.

PMID: 32535834 PMC: 7410879. DOI: 10.1007/s40744-020-00217-4.

References

Shinkai K, Yoshimura R, Ueda N, Okamoto K, Nakamura J . Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol. 2004; 24(1):11-7. DOI: 10.1097/01.jcp.0000104904.75206.19. View

Yang R, Lin Q, Gao H, Zhang P . Stress-related hormone norepinephrine induces interleukin-6 expression in GES-1 cells. Braz J Med Biol Res. 2014; 47(2):101-9. PMC: 4051180. DOI: 10.1590/1414-431X20133346. View

Drici M, Roux M, Candito M, Rimailho A, Morand P, Lapalus P . Influence of beta-blockade on circulating plasma levels of 3-methoxy-4-hydroxy phenylethylene glycol (MHPG) during exercise in moderate hypertension. Clin Exp Pharmacol Physiol. 1991; 18(12):807-11. DOI: 10.1111/j.1440-1681.1991.tb01399.x. View

Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J . Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33(4):722-6. DOI: 10.1016/j.pnpbp.2009.03.020. View

ATUK N, Hanks J, Weltman J, Bogdonoff D, Boyd D, Vance M . Circulating dihydroxyphenylglycol and norepinephrine concentrations during sympathetic nervous system activation in patients with pheochromocytoma. J Clin Endocrinol Metab. 1994; 79(6):1609-14. DOI: 10.1210/jcem.79.6.7989464. View

Yeung P, Buckley S, Pedder S, Dingemanse J . Determination of 3,4-dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid in human plasma by a simple and rapid high-performance liquid chromatography assay. J Pharm Sci. 1996; 85(4):451-3. DOI: 10.1021/js950361q. View

Kronfol Z, Remick D . Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000; 157(5):683-94. DOI: 10.1176/appi.ajp.157.5.683. View

Yoshimura R, Katsuki A, Atake K, Hori H, Igata R, Konishi Y . Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2017; 13:437-441. PMC: 5317346. DOI: 10.2147/NDT.S123121. View

Aguilar-Valles A, Jung S, Poole S, Flores C, Luheshi G . Leptin and interleukin-6 alter the function of mesolimbic dopamine neurons in a rodent model of prenatal inflammation. Psychoneuroendocrinology. 2011; 37(7):956-69. DOI: 10.1016/j.psyneuen.2011.11.003. View

10.

Kendler K, Mohs R, Davis K . The effects of diet and physical activity on plasma homovanillic acid in normal human subjects. Psychiatry Res. 1983; 8(3):215-23. DOI: 10.1016/0165-1781(83)90065-3. View

11.

Pech J, Forman J, Kessing L, Knorr U . Poor evidence for putative abnormalities in cerebrospinal fluid neurotransmitters in patients with depression versus healthy non-psychiatric individuals: A systematic review and meta-analyses of 23 studies. J Affect Disord. 2018; 240:6-16. DOI: 10.1016/j.jad.2018.07.031. View

12.

Petrulli J, Kalish B, Nabulsi N, Huang Y, Hannestad J, Morris E . Systemic inflammation enhances stimulant-induced striatal dopamine elevation. Transl Psychiatry. 2017; 7(3):e1076. PMC: 5404612. DOI: 10.1038/tp.2017.18. View

13.

. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386(9995):743-800. PMC: 4561509. DOI: 10.1016/S0140-6736(15)60692-4. View

14.

Ogawa S, Tsuchimine S, Kunugi H . Cerebrospinal fluid monoamine metabolite concentrations in depressive disorder: A meta-analysis of historic evidence. J Psychiatr Res. 2018; 105:137-146. DOI: 10.1016/j.jpsychires.2018.08.028. View

15.

Brydon L, Walker C, Wawrzyniak A, Whitehead D, Okamura H, Yajima J . Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. Brain Behav Immun. 2008; 23(2):217-24. PMC: 2637301. DOI: 10.1016/j.bbi.2008.09.007. View

16.

Fornaro M, Martino M, Battaglia F, Colicchio S, Perugi G . Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation. Neuropsychiatr Dis Treat. 2011; 7:51-6. PMC: 3056173. DOI: 10.2147/NDT.S16382. View

17.

Raison C, Borisov A, Majer M, Drake D, Pagnoni G, Woolwine B . Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry. 2008; 65(4):296-303. PMC: 2655138. DOI: 10.1016/j.biopsych.2008.08.010. View

18.

Yoshimura R, Umene-Nakano W, Suzuki A, Ueda N, Miyamoto K, Ikenouchi-Sugita A . Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Hum Psychopharmacol. 2009; 24(6):489-94. DOI: 10.1002/hup.1043. View

19.

Hamon M, Blier P . Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 45:54-63. DOI: 10.1016/j.pnpbp.2013.04.009. View

20.

Berk M, Wadee A, Kuschke R . Acute phase proteins in major depression. J Psychosom Res. 1997; 43(5):529-34. DOI: 10.1016/s0022-3999(97)00139-6. View